Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;30(7):1952-1961.
doi: 10.1038/s41591-024-02995-8. Epub 2024 May 17.

Prediction of DNA methylation-based tumor types from histopathology in central nervous system tumors with deep learning

Affiliations

Prediction of DNA methylation-based tumor types from histopathology in central nervous system tumors with deep learning

Danh-Tai Hoang et al. Nat Med. 2024 Jul.

Abstract

Precision in the diagnosis of diverse central nervous system (CNS) tumor types is crucial for optimal treatment. DNA methylation profiles, which capture the methylation status of thousands of individual CpG sites, are state-of-the-art data-driven means to enhance diagnostic accuracy but are also time consuming and not widely available. Here, to address these limitations, we developed Deep lEarning from histoPathoLOgy and methYlation (DEPLOY), a deep learning model that classifies CNS tumors to ten major categories from histopathology. DEPLOY integrates three distinct components: the first classifies CNS tumors directly from slide images ('direct model'), the second initially generates predictions for DNA methylation beta values, which are subsequently used for tumor classification ('indirect model'), and the third classifies tumor types directly from routinely available patient demographics. First, we find that DEPLOY accurately predicts beta values from histopathology images. Second, using a ten-class model trained on an internal dataset of 1,796 patients, we predict the tumor categories in three independent external test datasets including 2,156 patients, achieving an overall accuracy of 95% and balanced accuracy of 91% on samples that are predicted with high confidence. These results showcase the potential future use of DEPLOY to assist pathologists in diagnosing CNS tumors within a clinically relevant short time frame.

PubMed Disclaimer

References

    1. Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro. Oncol. 23, 1231–1251 (2021). - PubMed - PMC - DOI
    1. Bruner, J. M., Inouye, L., Fuller, G. N. & Langford, L. A. Diagnostic discrepancies and their clinical impact in a neuropathology referral practice. Cancer 79, 796–803 (1997). - PubMed - DOI
    1. Wu, Z. et al. Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. Neuro. Oncol. 24, 571–581 (2022). - PubMed - DOI
    1. Capper, D. et al. DNA methylation-based classification of central nervous system tumours. Nature 555, 469–474 (2018). - PubMed - PMC - DOI
    1. Pratt, D., Sahm, F. & Aldape, K. DNA methylation profiling as a model for discovery and precision diagnostics in neuro-oncology. Neuro. Oncol. 23, S16–S29 (2021). - PubMed - PMC - DOI

LinkOut - more resources